sputnik v covid-19 vaccine sputnik v covid-19 vaccine sputnik v (russian: спутник v, the brand name from rdif) or gam-covid-vac (russian: гам-ковид-вак, the name under which it is legally registered and produced) is an adenovirus viral vector vaccine for covid-19 developed by the gamaleya research institute of epidemiology and microbiology in russia. it is the world's first registered combination vector vaccine for the prevention of covid-19, having been registered on 11 august 2020 by the russian ministry of health. sputnik v covid-19 vaccinerussian ministry of health image of gam-covid-vac vialsvaccine descriptiontargetsars-cov-2vaccine typeviral vectorclinical datatrade namessputnik vспутник vother namesgam-covid-vacгам-ковид-вакlicense data eu ema: by inn routes ofadministrationintramuscularatc codej07bx03 (who) legal statuslegal status br: exceptional import ru: registered on 11 august 2020 full list of sputnik v vaccine authorizationsidentifiersdrugbankdb15848 part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal gam-covid-vac was initially approved for distribution in russia and then in 59 other countries (as of april 2021) on the preliminary results of phase i–ii studies eventually published on 4 september 2020. approval in early august of gam-covid-vac was met with criticism in mass media and discussions in the scientific community as to whether approval was justified in the absence of robust scientific research confirming safety and efficacy. a large-scale brazilian study from dec. 2020 to may 2021 confirmed its effectiveness and safety, as of oxford–astrazeneca's, i.e. above sinopharm bibp's. emergency mass-distribution of the vaccine began in december 2020 in countries including russia, argentina, belarus, hungary, serbia, pakistan (in limited quantities), the philippines (in limited quantities), and the united arab emirates. the sputnik v is currently registered and certified in 71 countries. however, as of april 2022 less than 2.5% of the people vaccinated worldwide have taken a sputnik v dose. in early 2022, as a result of the 2022 russian invasion of ukraine, the united states and other countries placed rdif on the list of sanctioned russian entities and people, significantly reducing sputnik v's future commercial prospects. the gam-covid-vac vaccine itself is available in two forms: frozen (vaccine storage: below −18 °c) and liquid (vaccine storage: from +2 to +8 °c, produced a little). in addition to the main vaccine, vaccines and its derivatives were registered: gam-covid-vac-lyo (russian: гам-ковид-вак-лио, no data on use), sputnik light (russian: спутник лайт, used for revaccination, as well as vaccination of foreigners in russia), gam-covid-vac-m (russian: гам-ковид-вак-м, for vaccination of adolescents 12–17 years old). medical uses the vaccine can be formulated in two ways: as a ready-to-use solution in water that is frozen at the common home-freezer storage temperature of −18 °c or 0 °f or lower, and as a freeze-dried (lyophlilized) powder, "gam-covid-vac-lyo", which can be stored at 2–8 °c or 36–46 °f. the freeze-dried powder must be reconstituted with sterile water before use. the lyophilized formulation of gam-covid-vac is similar to the smallpox vaccine, circumventing the need for continuous "colder chain" or cold-chain storage – as required for the pfizer–biontech and moderna vaccines – and allowing transportation to remote locations with reduced risk of vaccine spoilage. the first dose (based on ad26) is administered on the first day, and the second dose (based on ad5) is administered on the 21st day to boost immune response. both doses are administered into the deltoid muscle. sputnik light is a registered single-dose vaccine consisting of only the first dose of sputnik v. it is intended for areas with acute outbreaks and it will be used as a third (booster) dose for those who have received sputnik v at least 6 months earlier. on august 11, 2021, the developers of the sputnik v vaccine offered its 'sputnik light' (ad26) vaccine to pfizer for trial against the delta variant. effectiveness the effectiveness of covid-19 vaccines, or any other vaccine, is determined in a mass vaccination in a "real-world" setting (not in clinical trials). this is an assessment of how well the vaccine protects people from outcomes such as infection, symptomatic illness, hospitalization, and death. effectiveness is evaluated outside of clinical trials, which by contrast, evaluate the efficacy of the vaccine. a vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. effectiveness is generally expected to slowly decrease over time. on 25 august, a preliminary version of a case-control study indicated an unadjusted effectiveness of about 50% against symptomatic disease. the authors expected that adjusting for age and sex would increase the estimate, citing an increase from 66% to 81% when adjusting the data for effectiveness against hospitalization. a large-scale study in buenos aires from december 29, 2020, to may 15, 2021, with 663,602 participants aged 60 and older who received spunik v, the oxford–astrazeneca vaccine, or the sinopharm bibp vaccine observed an overall efficacy of 98% (95% ci, 95–99%) against covid-19-related deaths. the study noted that the three vaccines showed a similar effectiveness against death, and that the effectiveness against infection was similar to that of the oxford-astrazeneca vaccine and greater than that of the sinopharm bibp vaccine. initial effectiveness by variant doses severity of illness delta alpha 1 symptomatic not reported not reported hospitalization 35% (−21 to 65%) not reported 2 asymptomatic not reported 86% (84–87%) symptomatic not reported not reported hospitalization 81% (68–88%) not reported death not reported 98% (96–99%) case-control study with 13,894 participants from 3 july 2021 to 9 august 2021 in saint petersburg. the study awaits peer review. 22 january to 10 june 2021 in hungary. 14 to 55 days after the second dose, higher in women, 84% (66–92%), than in men, 76% (51–88%). increases to 85% (72–92%) 56 days or more after the second dose.a large-scale study was conducted in mexico and was published as a preprint, awaiting peer review (as of july 22, 2022). the study compared 793,487 adults vaccinated with different vaccines with 4,792,338 unvaccinated adults between december 24, 2020, and september 27, 2021.the results were as follows: effectiveness of vaccines in mexico (2021) vaccine incidental infection effectiveness hospitalization effectiveness mortality effectiveness spikevax 91.45% 78% 93.46% comirnaty 80.34% 84.26% 89.83% sputnik v 78.75% 81.38% 87.7% covishield 80.79% 80.23% 86.81% janssen 82.18% 77.33% 85.79% coronavac 71.93% 73.76% 80.38% convidecia 70.5% 72.31% 79.93% efficacy the vaccine efficacy of a covid-19 vaccine or any other vaccine is evaluated in controlled clinical trials. it is an estimate of how many people who received the vaccine got the disease compared to how many people who got a placebo had the same outcome. on 2 february 2021, an interim analysis from the moscow trial was published in the lancet reporting an efficacy of 91.6% (95% ci, 85.6–95.2%) after the second dose for all age groups, with no unusual side effects. for the age group of 60 years and older, the reported efficacy was 91.8%. on 12 may, a group of biostatisticians from russia, the us, france, italy and the netherlands questioned the efficacy results in a correspondence in the lancet, highlighting data discrepancies, substandard reporting, apparent errors and numerical inconsistencies and a very unlikely homogeneity in vaccine efficacy across age groups. the authors responded by saying that they had provided the regulatory authorities with all the data necessary for obtaining approval, and that the data included with the paper were enough for readers to confirm the reported vaccine efficacy. they also addressed the protocol queries, and said numerical inconsistencies were "simple typing errors that were formally corrected". in june 2022 a group of biostatisticians from australia and singapore published a paper suggesting that the almost identical efficacy for every age group from the lancet paper is very unlikely to occur in genuine experimental data. the group called for a thorough investigation of the lancet article, as well as the immediate release of anonymized individual patient data to an unbiased statistical expert, and suggested the article should be retracted. the lancet group recognized the concerns about the validity of data published in the article and invited the authors of the article to respond to these latest questions. adverse effects side effects are mostly mild and similar to other adenovirus vector vaccines such as the oxford-astrazeneca and the janssen vaccines. however, unlike the oxford-astrazeneca and janssen vaccines, and pfizer, evidence does not suggest a risk of vaccine-induced immune thrombotic thrombocytopenia. although a report from argentina published in the new england journal of medicine described fatal vaccine-induced thrombocytopenia and thrombosis in a young woman after receipt of sputnik-v. pharmacology sputnik v vaccination certificate issued in moscow gostiny dvor vaccination point. gam-covid-vac is a viral vector vaccine based on two recombinant replication-defective human adenoviruses: ad26 (serotype 26) and ad5 (serotype 5) replicated in hek 293 cells. the viruses contain the gene that encodes the full-length spike protein (s) of sars-cov-2 to stimulate an immune response. adenoviral vectors for expression of the sars-cov-2 spike protein have also been used in two other covid-19 vaccines. one is the janssen covid-19 vaccine, which utilizes the ad26cov2 viral vector based on the human virus ad26. for this vaccine, the cell line per.c6 is used to replicate the vector. another one, the oxford–astrazeneca covid‑19 vaccine, uses chimpanzee adenovirus (chadox1) as the vector. for both the oxford-astrazeneca covid-19 and gam-covid-vac vaccines the producer cells for the production of non-replicating adenoviral vectors were obtained from the hek 293 cell line. each dose of gam-covid-vac contains (1.0 ± 0.5) × 1011 virus particles. both ad26 and ad5 were modified to remove the e1 gene to prevent replication outside the hek 293 cells. for the production of the vaccine, to propagate adenoviral vectors in which the e1 gene was deleted, hek 293 cells are used, which express several adenoviral genes, including e1. however, although rare, homologous recombination between the inserted cellular sequence and the vector sequence can restore the replication capacity to the vector, with less than 100 replicating adenovirus particles per dose of the vaccine. chemistry the other ingredients (excipients) are the same, both quantitatively and qualitatively, in the two doses. tris(hydroxymethyl)aminomethane (buffer) sodium chloride (salt) sucrose (sugar) magnesium chloride hexahydrate disodium edta dihydrate (a chelation ligand; sequestrant) polysorbate 80 ethanol 95% water no adjuvants and no other components or ingredients